Actively Recruiting
Cycle-Length Mapping in Patients With Non-paroxysmal Atrial Fibrillation
Led by Ting-Yung Chang · Updated on 2025-09-09
80
Participants Needed
1
Research Sites
126 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The critical atrial substrates in maintaining persistent atrial fibrillation might be identified by Cycle-Length Mapping (CLM) module. Based on the results of multicenter study in Cycle-Length Mapping between Taipei Veterans General Hospital (Professor Shih-Ann Chen) and IRCCS San Donato Policlinic (Professor Carlo Pappone), targeted CLM driver-ablation provided significant benefits in terms of arrhythmia freedom in the treatment of persistent AF. These findings support a patient-tailored, mapping-based strategy for individuals affected by non-paroxysmal AF. The new ultra-high density mapping catheter, OPTRELL, will be available soon in Taiwan. Therefore, we proposed that the degree of atrial interstitial fibrosis detected by using both unipolar and bipolar voltage map in sinus rhythm and CLM in AF with OPTRELL™ Mapping Catheter would be further better characterization of the atrial substrate and could be potentially critical targeted in eliminating the sources of AF. As additional substrate mapping provided benefits compared to PVI alone in patients with persistent AF, we hypothesize that combination of electrophysiological and substrate-guided ablation strategy using CLM module with OPTRELL™ Mapping Catheter could be used to guide radiofrequency ablation in the patient with non-paroxysmal atrial fibrillation.
CONDITIONS
Official Title
Cycle-Length Mapping in Patients With Non-paroxysmal Atrial Fibrillation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients who sign informed consent and agree to follow-up
- Symptomatic AF refractory or intolerant to at least one Class 1 or 3 antiarrhythmic medication
- Persistent or permanent AF lasting beyond 7 days or requiring cardioversion
- Patients aged 20 years or older regardless of gender
You will not qualify if you...
- Presence of atrial or ventricular thrombus
- Allergy or unsuitability for contrast media use
- Pregnancy or inability to receive X-ray
- Severe renal insufficiency (GFR < 15 mg/dl or on dialysis)
- Autonomic nervous system disorder (e.g., respiratory apnea)
- Age less than 20 or greater than 90 years regardless of gender
- Contraindications to anticoagulation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Taipei Veterans General Hospital
Taipei, Outside US, Taiwan, 112
Actively Recruiting
Research Team
T
Ting-Yung Chang, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here